Agmatine is a substance that is classified as a novel food in the European Union. The Medicines and Healthcare products Regulatory Agency (MHRA) can confirm Agmatine is not present in any licensed medicines in the United Kingdom and there have been no clinical trials using agmatine either.
In order for the MHRA to authorise a medicine for use in the UK, a manufacturer has to apply to obtain a marketing authorisation. The MHRA makes its decision to approve a licence for a product based on demonstration of safety, quality and efficacy. Thus far, the MHRA has not received any application for Agmatine to be used for medical purposes.